AllSci News
Mirador acquires global rights to Kira's anti-C5a program in pre-merger deal
Mirador Therapeutics, Inc. (San Diego-based) has entered an exclusive worldwide license agreement with Kira Pharmaceuticals for KP-301, a long-acting...
Sanofi sues Pfizer and Moderna over Translate Bio mRNA delivery patents
Sanofi (Euronext: SAN) has filed two patent infringement lawsuits against Pfizer (NYSE: PFE) and Moderna (Nasdaq: MRNA), alleging that Comirnaty and Moderna’s…
REGENXBIO raises USD 100m amid pivotal year for gene therapy pipeline
Rockville, Maryland-based REGENXBIO Inc. (Nasdaq: RGNX) announced a proposed underwritten public offering of common stock, intending to raise $100 million...
Fabhalta becomes first complement inhibitor to win full FDA approval for IgAN
Novartis’s Fabhalta FDA approval IgAN decision, announced this week, converts the drug’s original accelerated clearance into a traditional approval for slowing kidney…
FDA accepts Camurus' resubmitted CAM2029 application for acromegaly review
Camurus AB (Nasdaq Stockholm: CAMX) said the US FDA has accepted for review its resubmitted New Drug Application for CAM2029, a long-acting subcutaneous...
Europe gives nod to Boehringer’s Jascayd as first new oral IPF drug in over a decade
The European Commission has granted marketing authorization for Jascayd (nerandomilast), Boehringer Ingelheim’s oral treatment for idiopathic pulmonary fibrosis (IPF) and progressive pulmonary…
La Jolla Labs and Unravel team on AI-driven ALS drug discovery with Ulm University partnership
La Jolla Labs Inc., Unravel Biosciences Inc., and Germany-based Ulm University have announced an ALS therapeutics collaboration combining artificial intelligence, RNA biology…
Mission Therapeutics divests MTX652 to Dimerix for USD 292m, pivots to CNS pipeline
Mission Therapeutics has divested MTX652, a Phase II-ready selective inhibitor of the mitochondrial enzyme USP30, to Australia-based Dimerix Limited (ASX:...
Texas A&M gets renewed NIH backing for MLL-rearranged leukemia drug discovery
Texas A&M University has received a USD 1.44 million fiscal year 2026 renewal of an NIH R01 grant from the National Cancer Institute to advance a...
Atai Therapeutics wins USD 2.73m NIH grant for non-hallucinogenic psychedelic compounds in opioid disorder
atai Therapeutics has received a USD 2.73 million UG3 cooperative agreement from the National Institute on Drug Abuse to advance non-hallucinogenic...
Emory backed by NIH to push EP2 antagonist for Alzheimer's towards IND
Emory University has received a USD 1.87 million NIH U01 grant to advance an EP2 receptor antagonist toward IND-enabling studies for Alzheimer's disease,...
Axsome advances first daytime oral therapy for cataplexy in narcolepsy toward FDA decision
New York-based Axsome Therapeutics, Inc. (Nasdaq: AXSM) said the US FDA has accepted for review its New Drug Application for AXS-12 (reboxetine), a...
BioNTech advances mRNA therapeutic HIV vaccine into randomized Phase I/II trial
BioNTech has registered a randomized, placebo-controlled Phase I/II clinical trial of BNT168, an mRNA vaccine designed to elicit HIV-specific immune...
Arbutus escalates LNP patent battle against Pfizer and BioNTech across North America and EU
Arbutus Biopharma and its exclusive licensee Genevant Sciences have expanded their patent campaign against Pfizer and BioNTech, filing new infringement lawsuits in…
Argenx taps Chai Discovery's AI for de novo antibody engineering in immunology
San Francisco-based Chai Discovery has entered a collaboration agreement with argenx (Euronext & Nasdaq: ARGX) granting the immunology company early access...
The AllSci Brief
Free, systematic R&D and deal news. Daily.